drugset / Trial / NCT02660489
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
Phase 2
Completed
44 enrolled
Imperial College London
Atopix Therapeutics, Ltd. · collabMedical Research Council · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459, in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection. The study is a double blind, randomised trial in which half the subjects will receive OC459 and the other half placebo, before being inoculated with rhinovirus, that would normally induce a worsening of asthma symptoms i.e. an exacerbation.
Timeline
- Start
- 2015-01
- Primary completion
- 2018-02
- Completion
- 2018-02
Outcome
Missed primary endpoint
registry analysis (superiority test); OC459 (CRTH2 Antagonist) vs Placebo; p = 0.78; Wilcoxon (Mann-Whitney) NCT02660489 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIMAPIPRANT | Small molecule | 50 mg | — |